<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">284</article-id><article-id pub-id-type="doi">10.36691/RJA284</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">ACTUALIZED INFORMATION ON THE USE OF LEVOCETIRIZINE IN URTICARIA</article-title><trans-title-group xml:lang="ru"><trans-title>АКТУАЛИЗИРОВАННАЯ ИНФОРМАЦИЯ ПО ПРИМЕНЕНИЮ ЛЕВОЦЕТИРИЗИНА ПРИ КРАПИВНИЦЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Astafieva</surname><given-names>N G</given-names></name><name xml:lang="ru"><surname>Астафьева</surname><given-names>Наталья Григорьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, зав. кафедрой клинической иммунологии и аллергологии</p></bio><email>astang@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kobzev</surname><given-names>D Y</given-names></name><name xml:lang="ru"><surname>Кобзев</surname><given-names>Д Ю</given-names></name></name-alternatives><bio xml:lang="ru"><p>профессор, директор бизнес-образования, школа здравоохранения и социальных наук.</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gamova</surname><given-names>I V</given-names></name><name xml:lang="ru"><surname>Гамова</surname><given-names>И В</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры клинической иммунологии и аллергологии.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perfilova</surname><given-names>I A</given-names></name><name xml:lang="ru"><surname>Перфилова</surname><given-names>И А</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, ассистент кафедры клинической иммунологии и аллергологии.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Udovichenko</surname><given-names>E N</given-names></name><name xml:lang="ru"><surname>Удовиченко</surname><given-names>Е Н</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, ассистент кафедры клинической иммунологии и аллергологии.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhaylova</surname><given-names>I E</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>И Э</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, ассистент кафедры клинической иммунологии и аллергологии.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Skuchaeva</surname><given-names>L V</given-names></name><name xml:lang="ru"><surname>Скучаева</surname><given-names>Л В</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры клинической иммунологии и аллергологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal state budgetary educational institution of higher professional education «Saratov state medical University named after V.I. Razumovsky» Ministry of health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Leeds Trinity University</institution></aff><aff><institution xml:lang="ru">Лидс Тринити университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2017</year></pub-date><volume>14</volume><issue>6</issue><issue-title xml:lang="en">NO6 (2017)</issue-title><issue-title xml:lang="ru">№6 (2017)</issue-title><fpage>69</fpage><lpage>82</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Фармарус Принт Медиа</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2019-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/284">https://rusalljournal.ru/raj/article/view/284</self-uri><abstract xml:lang="en"><p>Urticaria is a widespread disease with various phenotypes, duration and severity of the course, a pronounced effect on the quality of life. Despite the heterogeneity of the disease, a huge variety of provoking triggers, the activation of mast cells is still considered the key link in pathogenesis, and therefore antihistamines of the 2nd generation remain effective and safe drugs for treatment of urticaria. The process of improving antihistamines actively continues, one of the directions is the search for molecules based on the release of more active and safe enantiomers from already known drugs (example: levocetirizine from cetirizine). Information on levocetirizine, the efficacy and safety of which in the treatment of urticaria in both adults and children, has been demonstrated in a number of well-planned randomized controlled clinical trials, as well as in various preclinical studies, due to the accumulation of new data, the advent of generic drugs, and also a new scale for assessing the quality of clinical data in the GRADE system needs to be updated. The present review is devoted to solving this problem.</p></abstract><trans-abstract xml:lang="ru"><p>Крапивница является широко распространенным заболеванием с различными фенотипами, длительностью и тяжестью течения, выраженным влиянием на качество жизни. Несмотря на гетерогенность заболевания, огромное разнообразие провоцирующих стимулов, ключевым звеном патогенеза по-прежнему рассматривается активация тучных клеток, в связи с чем эффективными и безопасными фармпрепаратами для лечения крапивницы остаются антигистаминные препараты 2-го поколения. Совершенствование антигистаминных препаратов активно продолжается, одним из направлений является поиск молекул на основе выделения более активных и безопасных энантиомеров из уже известных препаратов (например, левоцетиризин из цетиризина). Информация по левоцетиризину, эффективность и безопасность которого при лечении крапивницы как у взрослых пациентов, так и у детей продемонстрирована в ряде хорошо спланированных рандомизированных контролируемых клинических испытаний, а также в ходе различных доклинических исследований, в связи с накоплением новых данных, появлением генерических препаратов, а также новой шкалы оценки качества клинических данных в системе GRADE нуждается в обновлении, чему и посвящен настоящий обзор.</p></trans-abstract><kwd-group xml:lang="en"><kwd>urticaria</kwd><kwd>levocetirizine</kwd><kwd>Allerway</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>крапивница</kwd><kwd>левоцетиризин</kwd><kwd>Аллервэй</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzo-za Z, Canonica GW et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69: 868-887.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Magerl M, Altrichter S, Borzova E, Gimenez-Arnau A, Grattan CEH, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016; 71: 780-802.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Колхир ПВ. Крапивница и ангиоотек. М. Практическая медицина, 2012: 363. ISBN 5-98811-228-5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Горячкина ЛА, Ненашева НМ, Борзова ЕЮ. Крапивница. Новости медицины и фармации, 2010; (322): 10-22.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Данилычева ИВ, Ильина НИ, Лусс ЛВ, Феденко ЕС, Шульженко АЕ. Федеральные клинические рекомендации по диагностике и лечению крапивницы. РАЖ. 2016; (1): 38-46.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Соколов ВИ. Введение в теоретическую стереохимию, М., 1982.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bonner WA. Origins of Chiral Homogeneity in Nature. Topics in Stereochemistry. 2007; 18: 1-96. DOI: 10.1002/9780470147276 ch1.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Pierson WE. Cetirizine: a unique second-generation antihistamine for treatment of rhinitis and chronic urticaria. Clin Ther. 1991; 13: 92-99.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Гущин ИС. Разнообразие противоаллергического действия цетиризина. Росс Аллергол Журн. 2006; (4): 33-44</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Клиническая аллергология и иммунология: руководство для практикующих врачей под ред. Л.А. Горячкиной и К.П. Кашкина. М., «Миклош». 2009: 432.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H1-histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002; 61(2): 391-399.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Day JH, Ellis AK, Rafeiro E. Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. Drugs Today (Barc.). 2004; 40: 415-421.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C et al. Absorption, distribution, metabolism and excretion of [14C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. 2001; 57: 571-582.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet. 2004; 43: 287-290.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hutt AJ, Valentova J. The chiral switch: the development of single enantiomer drugs from racemates. Acta Faccult Phar Univ Comenianae. 2003; 50: 7-23.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Canadian Task Force on the Periodic Health Examination. http://www.answers.com/topic/canadian-task-force-on-preventive-health-care.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig. 2006; 26: 1-11.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Sharma M, Bennett C, Cohen SN, Carter B. H1-antihista-mines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014; 14: CD006137. DOI: 10.1002/14651858.CD006137.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006; 154: 533-538.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, Finlay AY. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009; 64: 596-604. DOI: 10.1111/j.1398-9995.2008.01893.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Simons FE. Early Prevention of Asthma in Atopic Children Study Group. H1-antihistamine treatment in young atopic children: effect on urticaria. Ann Allergy Asthma Immunol. 2007; 99: 261-266.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Grading of Recommendations Assessment, Development and Evaluation. http://www.gradeworkinggroup.org.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y Flottorp S et al. Grading quality of evidence and strength of recommendations. GRADE Working Group. BMJ. 2004; 328: 1490.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 123-131. DOI: 10.1378/chest.08-0654.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Brozek JL, Bousquet J, Agache I. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140: 950-958. DOI: 10.1016/j.jaci.2017.03.050.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Гущин ИС. Перспективы совершенствования противоаллергического действия Hj-антигистаминных препаратов. Лечащий Врач. 2009; (5): 1-4.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Church DS, Church MK. Pharmacology of Antihistamines. World Allergy Organ J. 2011; 4: 22-27.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Simons FE, Simons KJ. Histamine and Hj-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2001; 128: 1139-1150.e4. DOI: 10.1016/j.jaci.2011.09.005.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Leurs R, Church M, Taglialatela M. Hj-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002; 32: 489-498.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Holgate ST, Canonica GW, Simons FER. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003; 33: 1305-1324.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Walsh GM. A review of the role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother. 2008; 9: 859-867.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2000; 52: 424-427.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Purohit A, Melac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol. 2003; 56: 388-394.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002; 88: 190-197.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacology. 2005; 5: 1-10.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003; 52: 49-50.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Трусова ОВ, Коростовцев ДС. Левоцетиризин (Ксизал). Характеристика препарата и опыт клинического применения. Аллергология. 2006; (2): 25-31. [Trusova OV, Korostovcev DS. Levocetirizin (Ksizal). Harakteristika preparata i opyt klinicheskogo primeneniya. Allergologiya. 2006; (2): 25-31 (In Russ.)].</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Jauregui I, Ferrer M, Montoro J, Davila I, Bartra J, A del Cu-villo et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007; 17: 41-52.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Колхир ПБ. Доказательная аллергология-иммунология. М., Практическая медицина. 2010: 528.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Фомина ДС, Горячкина ЛА. Выбор антигистаминного препарата с позиции доказательной медицины. Эффективная фармакотерапия. Аллергология и иммунология. 2012; (1): 18-24.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. World Health Organization; GA2LEN; AllerGen. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63: 8-160.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kanei A, Asano K, Kanai K, Furuta A, Sasaki K, Suzaki H. Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo. In Vivo. 2014; 28: 657-666.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Komatsuzaki T, Suzaki I, Hirano K, Kanai K, Asano K, Suzaki H. Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro. Biomed Res Int. 2013; 2013: 735835. DOI: 10.1155/2013/735835.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Hasala H, Janka-Junttila M, Moilanen E, Kankaanranta H. Levocitirizini and cytokine production and apoptosis of human eosinophilis. Allergy Asthma Proc. 2007; 28: 582-591.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Sharma M, Bennett C, Cohen SN, Carter B. Hj-antihista-mines for chronic spontaneous urticaria. Cochrane Database of Systematic Reviews. 2014, Issue 11. Art. No.: CD006137. DOI: 10.1002/14651858.CD006137.pub2.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Bocşan CI, Bujor AI, Miron N, Vesa ŞC, Deleanu D, Buzoianu AD. In vivo anti-inflammatory effect of Hj-antihistamines in allergic rhinitis. Balkan Med J. 2015; 32: 352-358.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. Journal of Clinical and Diagnostic Research. 2017; 11: 6-9.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, Martin M, Sánchez-Lopez J, Bartra et al. Effects of Rupatadine on Platelet-Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017; 27: 161-168. DOI: 10.18176/jiaci.0117.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Shih MY, Hsu JY, Weng YS, Fu LS. Influence of cetirizine and levocetirizine on two cytokines secretion in human airwy epithelial cells. Allergy Asthma Proc. 2008; 29: 480-485.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Simons FE, Simons KJ. Clinical pharmacology of H1-anti-histamines. Clin Allergy Immunol. 2002; 17: 141-178.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001; 15: 897-918.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Graziano FM, Cook EB, Stahl JL. Antihistamines and epithelial cells. Allergy Asthma Proc. 2000; 21: 129-140. PMID: 10892513.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Ashenager MS, Grgela T, Aragane Y, Kawada A. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol. 2007; 1: 20-26.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 2001; 56: 50-57.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Гущин ИС. Полифункциональные противоаллергические возможности антагониста Н1рецепторов - левоцетиризина. Росс Аллергол Журн. 2014; (2): 11-24. [Gushchin IS. Polifunkcional’nye protivoallergicheskie vozmozhnosti an-tagonista Nj-receptorov - levocetirizina. Russian Journal of allergy. 2014; 2: 11-24 (In Russ.)].</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Mahmoud F, Arifhodzic N, Haines D, Novotney L. Levo-cetirizine modulates lymphocyte activation in patients with allergic rhinitis. J Pharmacol Sci. 2008; 108: 149-156.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Marcucci F, Sensi LG, Abate P, Allocca G, Ugolini E, Di Cara G et al. Anti-inflammatory activity and clinical efficacy of a 3-month levocetirizine therapy in mite-allergic children. Inflamm Allergy Drug Targets. 2011; 10: 32-38.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005; 5: 1800-1808.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lau-que D, Charpentier S. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. Ann Emerg Med. 2017; 2: 196-644. DOI: 10.1016/j.anne-mergmed.2017.03.006.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008; 15: 2173-2191.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Карева ЕН. Выбор антигистаминного препарата: взгляд фармаколога. РМЖ «Медицинское обозрение». 2016; 12: 811-816</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Hu Y, Sieck DE, Hsu WH. Why are second-generation Hj-antihistamines minimally sedating? Eur J Pharmacol. 2015; 765: 100-106.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Inami A, Matsuda R, Grobosch T, Komamura H, Takeda K, Yamada Y et al. A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Hum Psychopharmacol Clin Exp. 2016; 31: 167-177. DOI: 10.1002/hup.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Paśko P, Rodacki T, Domagala-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation Hj-antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother. 2017; 93: 27-39. DOI: 10.1016/j. biopha.2017.06.008.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Snidvongs К, Seresirikachorn К, Khattiyawittayakun L, Chitsuthipakorn W. Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Drugs. 2017; 77: 175-186. DOI: 10.1007/s40265-016-0682-0).</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Klimek L. Levocetirizine: from scientific evidence to a potent modern-day treatment of today’s allergic patients. Drugs Today (Barc.). 2009; 45: 213-225.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>FDA/CDER SBIA Chronicles. Drugs in Pregnancy and Lactation: Improved Benefit-Risk Information. January 22, 2015. Accessed July 25, 2016 at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Gonzalez-Estrada A, Geraci SA. Allergy Medications During Pregnancy. Am J Med Sci. 2016; 352: 326-31. DOI: 10.1016/j.amjms.2016.05.030.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Newton ER, Hale TW. Drugs in Breast Milk. Clin Obstet Gynecol. 2015; 58: 868-884. DOI: 10.1097/GRF.0000000000000142.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Астафьева НГ, Гамова ИВ, Удовиченко ЕИ, Перфилова ИА. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010; (5): 62-68.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Абатуров АЕ, Борисова ТП. Дифференцированный подход к назначению антигистаминных препаратов при аллергических заболеваниях в детском возрасте. Здоровье ребенка. 2016; (5): 121-127. DOI: http://dx.doi.org/10.22141/2224-0551.5.73.2016.78309</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatolog Treat. 2017; 25: 1-5. DOI: 10.1080/09546634.2016.1246705.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Аллергология. Федеральные клинические рекомендации. Главные редакторы: акад. РАН Р.М. Хаитов, проф. Н.И. Ильина. М., «Фармарус Принт Медиа». 2014: 126.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Popov TA. Challenges in the management of chronic urticaria. World Allergy Organ J. 2011; 4: 28-31.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Bachert C, Maspero J. Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma. 2011; 48: 965-973. DOI: 10.3109/02770903.2011.616616.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Kim JH, Kwon HJ, Jang YJ. Levocetirizine inhibits rhinovirusinduced up-regulation of fibrogenic and angiogenic factors in nasal polyp fibroblasts. Am J Rhinol Allergy. 2011; 25: 416-420. DOI: 10.2500/ajra.2011.25.3684.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Jang YJ, Wang JH, Kim JS, Kwon HJ, Yeo NK, Lee BJ. Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells. Antiviral Res. 2009; 81: 226-233. DOI: 10.1016/j.antiviral.2008.12.001.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015; 11: CD009345. DOI: 10.1002/14651858.CD009345.pub2.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Al-Kasmi B, Alsirawan MB, Bashimam M, El-Zein H. Mechanical microencapsulation: The best technique in taste masking for the manufacturing scale - Effect of polymer encapsulation on drug targeting. J Control Release. 2017; 260: 134-141. DOI: 10.1016/j.jconrel.2017.06.002.</mixed-citation></ref></ref-list></back></article>
